Drug Type Small molecule drug |
Synonyms Taminadenant, NIR 178, PBF-509 + [1] |
Target |
Action antagonists |
Mechanism A2aR antagonists(Adenosine A2a receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC10H8BrN7 |
InChIKeyATFXVNUWQOXRRU-UHFFFAOYSA-N |
CAS Registry1337962-47-6 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | United States | 28 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Japan | 28 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Argentina | 28 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Australia | 28 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Austria | 28 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Belgium | 28 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Czechia | 28 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | France | 28 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Germany | 28 Aug 2017 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Italy | 28 Aug 2017 |
Phase 2 | Triple Negative Breast Cancer ER Negative | PR Negative | HER2 Negative | 30 | hkcbkyuyka(lhuoirjice) = jvmykvcmzu yivozyelkc (ubzvfjhgrf ) View more | Positive | 08 Dec 2022 | ||
NCT03549000 (AACR2022) Manual | Phase 1 | 105 | NZV930(60-1000 mg Q2W) or NZV930(200-600 mg Q2W) + spartalizumab (400 mg Q4W) or NZV930(200-600 mg Q2W) + taminadenant (80-240 mg Q2W) or NZV930(200-600 mg Q2W) + spartalizumab (400 mg Q4W) + taminadenant (80-240 mg BID) | auqcucguej(clyhfpodii) = eocvcrtvom ljqyuyzucb (phhnxqgtqz ) View more | Positive | 08 Apr 2022 | |
Phase 2 | Metastatic Microsatellite Stable Colorectal Carcinoma Microsatellite Stable (MSS) | 58 | cdiysklrax(vvaaddozob) = rpizjwzmyz cqfkmandar (ffrjaeoiak, 0.0 - 9.2) View more | Positive | 16 Sep 2021 | ||
Phase 1/2 | Non-Small Cell Lung Cancer Second line | 24 | idywxhgswt(vlzwtjlxag) = none pxyaibmcoa (csboromgrb ) View more | Positive | 03 Jun 2018 |